Adial Pharmaceuticals, Inc. Research and Development Expense
Adial Pharmaceuticals, Inc. (ADIL) reported Research and Development Expense of $440.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-14
- Adial Pharmaceuticals, Inc. research and development expense for the quarter ending 2026-06-30 was $440.00K, a 39.89% decline year-over-year.
- Adial Pharmaceuticals, Inc. research and development expense for the quarter ending 2026-03-31 was $432.53K, a 42.09% decline year-over-year.
- Adial Pharmaceuticals, Inc. research and development expense for the quarter ending 2025-12-31 was $619.40K, a 15.24% decline year-over-year.
- Adial Pharmaceuticals, Inc. research and development expense for the quarter ending 2025-09-30 was $521.07K, a 49.49% decline year-over-year.
- Adial Pharmaceuticals, Inc. research and development expense for fiscal 2025 was $2.62M, a 18.88% decline from fiscal 2024.
- Adial Pharmaceuticals, Inc. research and development expense for fiscal 2024 was $3.23M, a 154.86% increase from fiscal 2023.
- Adial Pharmaceuticals, Inc. research and development expense for fiscal 2023 was $1.27M, a 35.03% decline from fiscal 2022.
- Adial Pharmaceuticals, Inc. research and development expense for fiscal 2022 was $1.95M, a 76.77% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $440.00K 10-Q · filed 2026-08-14 | $873.00K 10-Q · filed 2026-08-14 | $1.49M derived: sum of 3 quarters · filed 2026-08-14 | $2.01M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2026-03-31 | $432.53K 10-Q · filed 2026-05-08 | $1.05M derived: sum of 2 quarters · filed 2026-05-08 | $1.57M derived: sum of 3 quarters · filed 2026-05-08 | $2.30M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-12-31 | $619.40K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $1.14M derived: sum of 2 quarters · filed 2026-03-05 | $1.87M derived: sum of 3 quarters · filed 2026-08-14 | $2.62M 10-K · filed 2026-03-05 | ||||
| 2025-09-30 | $521.07K 10-Q · filed 2025-11-13 | $1.25M derived: sum of 2 quarters · filed 2026-08-14 | $2.00M 10-Q · filed 2025-11-13 | $2.73M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-06-30 | $732.00K 10-Q · filed 2026-08-14 | $732.32K 10-Q · filed 2025-08-13 | $1.48M 10-Q · filed 2026-08-14 | $1.48M 10-Q · filed 2025-08-13 | $2.21M derived: sum of 3 quarters · filed 2026-08-14 | $3.24M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-03-31 | $746.89K 10-Q · filed 2026-05-08 | $1.48M derived: sum of 2 quarters · filed 2026-05-08 | $2.51M derived: sum of 3 quarters · filed 2026-05-08 | $3.52M derived: sum of 4 quarters · filed 2026-05-08 | ||||
| 2024-12-31 | $730.79K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $1.76M derived: sum of 2 quarters · filed 2026-03-05 | $2.77M derived: sum of 3 quarters · filed 2026-03-05 | $3.23M 10-K · filed 2026-03-05 | ||||
| 2024-09-30 | $1.03M 10-Q · filed 2025-11-13 | $2.04M derived: sum of 2 quarters · filed 2025-11-13 | $2.50M 10-Q · filed 2025-11-13 | $2.76M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | $1.01M 10-Q · filed 2025-08-13 | $1.47M 10-Q · filed 2025-08-13 | $1.73M derived: sum of 3 quarters · filed 2025-08-13 | $1.94M derived: sum of 4 quarters · filed 2025-08-13 | ||||
| 2024-03-31 | $454.28K 10-Q · filed 2025-05-14 | $718.72K derived: sum of 2 quarters · filed 2025-05-14 | $925.84K derived: sum of 3 quarters · filed 2025-05-14 | $1.36M derived: sum of 4 quarters · filed 2025-05-14 | ||||
| 2023-12-31 | $264.44K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $471.56K derived: sum of 2 quarters · filed 2025-03-04 | $901.46K derived: sum of 3 quarters · filed 2025-03-04 | $1.27M 10-K · filed 2025-03-04 | ||||
| 2023-09-30 | $207.13K 10-Q · filed 2024-11-13 | $637.02K derived: sum of 2 quarters · filed 2024-11-13 | $1.00M 10-Q · filed 2024-11-13 | $1.85M derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | $429.90K 10-Q · filed 2024-08-13 | $795.51K 10-Q · filed 2024-08-13 | $1.64M derived: sum of 3 quarters · filed 2024-08-13 | $2.33M derived: sum of 4 quarters · filed 2024-08-13 | ||||
| 2023-03-31 | $676.43K 10-Q · filed 2023-05-12 | $1.21M derived: sum of 2 quarters · filed 2024-04-01 | $1.90M derived: sum of 3 quarters · filed 2024-04-01 | $2.58M derived: sum of 4 quarters · filed 2024-04-01 | ||||
| 2022-12-31 | $531.84K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $1.23M derived: sum of 2 quarters · filed 2024-04-01 | $1.91M derived: sum of 3 quarters · filed 2024-04-01 | $1.95M 10-K · filed 2024-04-01 | $4.18M 10-K · filed 2023-03-30 | |||
| 2022-09-30 | $696.07K 10-Q · filed 2023-11-14 | $1.24M 10-Q · filed 2022-11-14 | $1.38M derived: sum of 2 quarters · filed 2023-11-14 | $1.42M 10-Q · filed 2023-11-14 | $3.04M 10-Q · filed 2022-11-14 | $4.31M derived: sum of 4 quarters · filed 2023-11-14 | ||
| 2022-06-30 | $679.97K 10-Q/A · filed 2023-10-30 | $1.20M 10-Q · filed 2022-08-15 | $722.39K 10-Q/A · filed 2023-10-30 | $1.80M 10-Q · filed 2022-08-15 | $3.61M derived: sum of 3 quarters · filed 2023-10-30 | $5.30M derived: sum of 4 quarters · filed 2023-10-30 | ||
| 2022-03-31 | $596.34K 10-Q · filed 2023-05-12 | $2.93M derived: sum of 2 quarters · filed 2023-05-12 | $4.62M derived: sum of 3 quarters · filed 2023-05-12 | $6.94M derived: sum of 4 quarters · filed 2023-05-12 | ||||
| 2021-12-31 | $2.33M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $4.02M derived: sum of 2 quarters · filed 2023-03-30 | $6.34M derived: sum of 3 quarters · filed 2023-03-30 | $8.40M 10-K · filed 2023-03-30 | ||||
| 2021-09-30 | $1.69M 10-Q · filed 2022-11-14 | $4.01M derived: sum of 2 quarters · filed 2022-11-14 | $6.06M 10-Q · filed 2022-11-14 | $8.13M derived: sum of 4 quarters · filed 2022-11-14 | ||||
| 2021-06-30 | $2.32M 10-Q · filed 2022-08-15 | $4.37M 10-Q · filed 2022-08-15 | $6.43M derived: sum of 3 quarters · filed 2022-08-15 | $8.28M derived: sum of 4 quarters · filed 2022-08-15 | ||||
| 2021-03-31 | $2.05M 10-Q · filed 2022-05-16 | $4.12M derived: sum of 2 quarters · filed 2022-05-16 | $5.96M derived: sum of 3 quarters · filed 2022-05-16 | $6.85M derived: sum of 4 quarters · filed 2022-05-16 | ||||
| 2020-12-31 | $2.06M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $3.91M derived: sum of 2 quarters · filed 2022-03-28 | $4.80M derived: sum of 3 quarters · filed 2022-03-28 | $5.85M 10-K · filed 2022-03-28 | ||||
| 2020-09-30 | $1.85M 10-Q · filed 2021-11-15 | $2.74M derived: sum of 2 quarters · filed 2021-11-15 | $3.79M 10-Q · filed 2021-11-15 | $5.00M derived: sum of 4 quarters · filed 2021-11-15 | ||||
| 2020-06-30 | $888.01K 10-Q · filed 2021-08-12 | $1.94M 10-Q · filed 2021-08-12 | $3.15M derived: sum of 3 quarters · filed 2021-08-12 | $4.02M derived: sum of 4 quarters · filed 2021-08-12 | ||||
| 2020-03-31 | $1.06M 10-Q · filed 2021-05-17 | $1.05M 10-Q · filed 2020-05-14 | $2.26M derived: sum of 2 quarters · filed 2021-05-17 | $3.13M derived: sum of 3 quarters · filed 2021-05-17 | $4.34M derived: sum of 4 quarters · filed 2021-05-17 | |||
| 2019-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-22 | $2.07M derived: sum of 2 quarters · filed 2021-03-22 | $3.28M derived: sum of 3 quarters · filed 2021-03-22 | $3.97M 10-K · filed 2021-03-22 | ||||
| 2019-09-30 | $864.28K 10-Q · filed 2020-11-13 | $2.07M derived: sum of 2 quarters · filed 2020-11-13 | $2.76M 10-Q · filed 2020-11-13 | $2.81M derived: sum of 4 quarters · filed 2020-11-13 | ||||
| 2019-06-30 | $1.21M 10-Q · filed 2020-08-13 | $1.90M 10-Q · filed 2020-08-13 | $1.94M derived: sum of 3 quarters · filed 2020-08-13 | $2.13M derived: sum of 4 quarters · filed 2020-08-13 | ||||
| 2019-03-31 | $686.91K 10-Q · filed 2020-05-14 | $734.53K derived: sum of 2 quarters · filed 2020-05-14 | $922.97K derived: sum of 3 quarters · filed 2020-05-14 | $999.87K derived: sum of 4 quarters · filed 2020-05-14 | ||||
| 2018-12-31 | $47.62K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-20 | $236.06K derived: sum of 2 quarters · filed 2020-03-20 | $312.95K derived: sum of 3 quarters · filed 2020-03-20 | $368.46K 10-K · filed 2020-03-20 | ||||
| 2018-09-30 | $188.44K 10-Q · filed 2019-11-14 | $265.33K derived: sum of 2 quarters · filed 2019-11-14 | $320.84K 10-Q · filed 2019-11-14 | $372.81K derived: sum of 4 quarters · filed 2019-11-14 | ||||
| 2018-06-30 | $76.89K 10-Q · filed 2018-09-10 | $132.40K 10-Q · filed 2019-08-13 | $184.37K derived: sum of 3 quarters · filed 2019-08-13 | $212.17K derived: sum of 4 quarters · filed 2019-08-13 | ||||
| 2018-03-31 | $55.51K 10-Q · filed 2019-05-13 | $107.48K derived: sum of 2 quarters · filed 2019-05-13 | $135.28K derived: sum of 3 quarters · filed 2019-05-13 | $193.14K derived: sum of 4 quarters · filed 2019-05-13 | ||||
| 2017-12-31 | $51.97K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-19 | $79.77K derived: sum of 2 quarters · filed 2019-02-19 | $137.63K derived: sum of 3 quarters · filed 2019-02-19 | $182.11K 10-K · filed 2019-02-19 | ||||
| 2017-09-30 | $27.80K 10-Q · filed 2018-11-14 | $85.66K derived: sum of 2 quarters · filed 2018-11-14 | $130.14K 10-Q · filed 2018-11-14 | |||||
| 2017-06-30 | $57.86K 10-Q · filed 2018-09-10 | $102.34K 10-Q · filed 2018-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |